News
QURE
14.42
+3.30%
0.46
Analysts See 19% Gains Ahead For FHLC
NASDAQ · 2d ago
uniQure (QURE) Gets a Buy from H.C. Wainwright
TipRanks · 2d ago
Weekly Report: what happened at QURE last week (0707-0711)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and uniQure (QURE)
TipRanks · 4d ago
Weekly Report: what happened at QURE last week (0630-0704)?
Weekly Report · 07/07 09:09
uniQure’s CMO Cashes Out: A Look at the Recent Stock Sale
TipRanks · 07/02 02:03
H.C. Wainwright Sticks to Their Buy Rating for uniQure (QURE)
TipRanks · 06/30 16:15
Analysts’ Top Healthcare Picks: uniQure (QURE), TuHURA Biosciences (HURA)
TipRanks · 06/30 11:10
Weekly Report: what happened at QURE last week (0623-0627)?
Weekly Report · 06/30 09:09
uniQure Directors Make Major Stock Moves!
TipRanks · 06/25 02:02
Weekly Report: what happened at QURE last week (0616-0620)?
Weekly Report · 06/23 09:09
uniQure’s CLO Makes a Notable Stock Sale!
TipRanks · 06/21 02:06
Insider Sale: Chief Legal Officer of $QURE Sells 4,670 Shares
NASDAQ · 06/20 23:45
uniQure: Price And Value Have Caught Up
Seeking Alpha · 06/17 11:25
Weekly Report: what happened at QURE last week (0609-0613)?
Weekly Report · 06/16 09:09
uniQure appoints Kylie O’Keefe as chief customer, strategy officer
TipRanks · 06/11 12:15
uniQure N.V. Appoints Kylie O’Keefe as Chief Customer and Strategy Officer to Drive AMT-130 Commercialization in Huntington’s Disease
NASDAQ · 06/11 12:14
Weekly Report: what happened at QURE last week (0602-0606)?
Weekly Report · 06/09 09:09
RFK Jr. looks to fast track rare disease drug approvals
Seeking Alpha · 06/06 13:01
Rare Stock Picks In May 2025 - From 27 Discerning Analysts
Seeking Alpha · 06/06 12:00
More
Webull provides a variety of real-time QURE stock news. You can receive the latest news about Uniqure through multiple platforms. This information may help you make smarter investment decisions.
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.